OUTCOMES OF CORE DECOMPRESSION WITH PLATELET RICH PLASMA AND ORAL IBADRONATE SUPPLEMENTATION IN OSTEONECROSIS OF FEMORAL HEAD IN SICKLE CELL POSITIVE YOUNG ADULTS.

Main Article Content

Dr Arvind Kumar
Dr Apurva Patel
Dr Sonal Lakum
Dr Mayank Gajera
Dr Harshil barot
Dr Aliasgar Rampurwala

Keywords

ONFH, SCD, PRP, Ibandronate

Abstract

BACKGROUND: Osteonecrosis of Femoral head (ONFH) is a common and serious complication of sickle cell disease (SCD). Without early treatment intervention, incidence of femoral head collapse and secondary osteoarthritis are very high and occur early in these patients. Aim of this study is to relief the symptoms, improve the functional outcomes for better activity of daily life (ADL) and delay the progression of head collapse.


METHODS: In this retrospective study,40 hips in 30 pts were selected by inclusion and exclusion criteria. Mean age was 25 years. All selected cases were belonging to stage I, II and IIIa according to Modified Ficat and Arlet classification. In all pts core decompression were done by making two core tracks of 6 mm diameter with the help of Hollow-mill and PRP was injected in both core track and packed with bone wax. Oral Ibandronate given in all pts for 6 months. Percutaneous adductor tenotomy was performed in stage IIB and IIIa. Functional outcome were assessed by Modified Harris Hip Score (MHHS) and radiological assessment done by serial X-rays and MRI. Follow up were done up to 96 weeks.


 RESULTS: Average operative time was 30 minutes, average blood loss was 30 ml, average hospital stay was 7.5 days. Infection rate was only 5%. We observed 35% excellent, 45% good, 10% fair and 10% poor outcomes.


CONCLUSION:  We concluded that this technique is a relatively safe, cost effective, easy to perform, has very low complications rate and effective treatment option for the younger patients with ONFH in SCD

Abstract 62 | pdf Downloads 63

References

1. Murphy R.C, Shaprio S (1945); The pathology of sickle cell disease. Ann. Intern. Med.23;376
2. Diggs L.W (1965); sickle cell crisis. Amer. J. Clin. Path. 44; 1.
3. Gangji V, Hauzeur JP. (2005); Treatment of Osteonecrosis of the femoral head with implantation of autologus bone marrow cells. JBJS 87,106-112
4. Lai K A, Shen WJ, Yang CY et al (2005); use of alandronate to prevent early collapse of femoral head in patients with nontraumatic Osteonecrosis. JBJS Am;87;2155-9.
5. Mukisi-Mukaza M, Manicom O, Alexis C, et al. (2009); Treatment of sickle cell disease’s hip necrosis by core decompression: a prospective case control study. Orthop. Traumatol. Surg. Res. 95,498-504.
6. Sen RK, Tripathy SK, Agrawal S, et al. (2012); Early results of core decompression and autologus bone marrow mononuclear cell instillation in femoral head Osteonecrosis. J. Arthroplasty 27,679-686.
7. Kang P, Pei F, Shen B, Zhou Z, Yang J (2012); Are the result of multiple drilling and Alandronate for Osteonecrosis of the femoral head better than those of multiple drilling? A pilot study. JBS, 79(1); 67-72
8. Kim SY, Kim DH, Park IH etal. (2004); Multiple drilling compared with standard core decompression for the treatment of Osteonecrosis of femoral head. JBJS(Br),86-B,149.
9. Hernigou P, Beaujean F (2002); Treatment of Osteonecrosis with autologus bone marrow grafting, Clin. Ortho. Relat Res (405);14-23.
10. Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H (2006); does alandronate prevent collapse in Osteonecrosis of femoral head? Clin Orthop Relat Res, 443; 273-9.
11. Stulberg BN, et al (1991)osteonecrosis of femoral head. A prospective randomized treatment protocol.Clin Orthop Relat Res,July1991;(268):140-51
12. Al-Jafar HA, Al-Ali NS, Ali A, Alobaid A (2016); medical and surgical treatment options for early Osteonecrosis in sickle cell disease. Ann. Hematol. Oncol. 2016; 3(5):1092